As reported by Jason Harris in Targeted Oncology,
“Immune checkpoint inhibitors (ICIs), alone or in combination, are associated with increased incidence of some cardiovascular toxicities in patients with cancer, according to results from a cross-trial pooled analysis presented in a poster at the 2018 ASCO Annual Meeting.
View article here
Source: TargetedONC

Pin It on Pinterest